One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services

L Bauld, K A Boyd, A H Briggs, John Chesterman, Janet Ferguson, Ken Judge, Rosemary Hiscock

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

An observational study examining 1-year follow-up of clients of two National Health Service smoking cessation services in Glasgow was used to inform a cost-effectiveness analysis. One service involved 7 weeks of group-based support (n = 411) and the other consisted of up to 12 weeks of one-to-one counseling with pharmacists (n = 1,374). Pharmacological aids to quitting (e.g., nicotine replacement therapy) were available to all clients. Quit rates were calculated for each service at 52 weeks after the quit date, and these were used for an economic evaluation of both the annual and the lifetime cost-effectiveness of the pharmacy- and group-based interventions in comparison with a baseline "self-quit" scenario. The annual cost-effectiveness model established the incremental cost per 52-week quitter, while a Markov model was developed for the lifetime analysis to estimate the potential lifetime outcomes in terms of cost per quality-adjusted life years (QALY) gained, to account for the benefits quitters will receive in terms of extended life years and improvements in quality of life from smoking cessation. The proportion of carbon monoxide-validated quitters from both services combined fell from 22.5% at 4-week follow-up to 3.6% at 52 weeks. The group service achieved a higher quit rate (6.3%) than the pharmacy service (2.8%) but was more intensive and required greater overhead costs. The lifetime analysis resulted in an incremental cost per QALY of 4,800 pound for the group support and 2,600 pound for pharmacy one-to-one counseling. Despite disappointing 1-year quit rates, both services were considered to be highly cost-effective.
Original languageEnglish
Pages (from-to)135-145
Number of pages11
JournalNicotine & Tobacco Research
Volume13
Issue number2
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Cost-Benefit Analysis
Costs and Cost Analysis
Quality-Adjusted Life Years
Smoking Cessation
Counseling
Pharmaceutical Services
National Health Programs
Carbon Monoxide
Nicotine
Pharmacists
Observational Studies
Quality of Life
Pharmacology
Therapeutics

Cite this

One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services. / Bauld, L; Boyd, K A; Briggs, A H; Chesterman, John; Ferguson, Janet; Judge, Ken; Hiscock, Rosemary.

In: Nicotine & Tobacco Research, Vol. 13, No. 2, 02.2011, p. 135-145.

Research output: Contribution to journalArticle

Bauld, L ; Boyd, K A ; Briggs, A H ; Chesterman, John ; Ferguson, Janet ; Judge, Ken ; Hiscock, Rosemary. / One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services. In: Nicotine & Tobacco Research. 2011 ; Vol. 13, No. 2. pp. 135-145.
@article{9edbaea417314bb787885541274910af,
title = "One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services",
abstract = "An observational study examining 1-year follow-up of clients of two National Health Service smoking cessation services in Glasgow was used to inform a cost-effectiveness analysis. One service involved 7 weeks of group-based support (n = 411) and the other consisted of up to 12 weeks of one-to-one counseling with pharmacists (n = 1,374). Pharmacological aids to quitting (e.g., nicotine replacement therapy) were available to all clients. Quit rates were calculated for each service at 52 weeks after the quit date, and these were used for an economic evaluation of both the annual and the lifetime cost-effectiveness of the pharmacy- and group-based interventions in comparison with a baseline {"}self-quit{"} scenario. The annual cost-effectiveness model established the incremental cost per 52-week quitter, while a Markov model was developed for the lifetime analysis to estimate the potential lifetime outcomes in terms of cost per quality-adjusted life years (QALY) gained, to account for the benefits quitters will receive in terms of extended life years and improvements in quality of life from smoking cessation. The proportion of carbon monoxide-validated quitters from both services combined fell from 22.5{\%} at 4-week follow-up to 3.6{\%} at 52 weeks. The group service achieved a higher quit rate (6.3{\%}) than the pharmacy service (2.8{\%}) but was more intensive and required greater overhead costs. The lifetime analysis resulted in an incremental cost per QALY of 4,800 pound for the group support and 2,600 pound for pharmacy one-to-one counseling. Despite disappointing 1-year quit rates, both services were considered to be highly cost-effective.",
author = "L Bauld and Boyd, {K A} and Briggs, {A H} and John Chesterman and Janet Ferguson and Ken Judge and Rosemary Hiscock",
year = "2011",
month = "2",
doi = "10.1093/ntr/ntq222",
language = "English",
volume = "13",
pages = "135--145",
journal = "Nicotine & Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services

AU - Bauld, L

AU - Boyd, K A

AU - Briggs, A H

AU - Chesterman, John

AU - Ferguson, Janet

AU - Judge, Ken

AU - Hiscock, Rosemary

PY - 2011/2

Y1 - 2011/2

N2 - An observational study examining 1-year follow-up of clients of two National Health Service smoking cessation services in Glasgow was used to inform a cost-effectiveness analysis. One service involved 7 weeks of group-based support (n = 411) and the other consisted of up to 12 weeks of one-to-one counseling with pharmacists (n = 1,374). Pharmacological aids to quitting (e.g., nicotine replacement therapy) were available to all clients. Quit rates were calculated for each service at 52 weeks after the quit date, and these were used for an economic evaluation of both the annual and the lifetime cost-effectiveness of the pharmacy- and group-based interventions in comparison with a baseline "self-quit" scenario. The annual cost-effectiveness model established the incremental cost per 52-week quitter, while a Markov model was developed for the lifetime analysis to estimate the potential lifetime outcomes in terms of cost per quality-adjusted life years (QALY) gained, to account for the benefits quitters will receive in terms of extended life years and improvements in quality of life from smoking cessation. The proportion of carbon monoxide-validated quitters from both services combined fell from 22.5% at 4-week follow-up to 3.6% at 52 weeks. The group service achieved a higher quit rate (6.3%) than the pharmacy service (2.8%) but was more intensive and required greater overhead costs. The lifetime analysis resulted in an incremental cost per QALY of 4,800 pound for the group support and 2,600 pound for pharmacy one-to-one counseling. Despite disappointing 1-year quit rates, both services were considered to be highly cost-effective.

AB - An observational study examining 1-year follow-up of clients of two National Health Service smoking cessation services in Glasgow was used to inform a cost-effectiveness analysis. One service involved 7 weeks of group-based support (n = 411) and the other consisted of up to 12 weeks of one-to-one counseling with pharmacists (n = 1,374). Pharmacological aids to quitting (e.g., nicotine replacement therapy) were available to all clients. Quit rates were calculated for each service at 52 weeks after the quit date, and these were used for an economic evaluation of both the annual and the lifetime cost-effectiveness of the pharmacy- and group-based interventions in comparison with a baseline "self-quit" scenario. The annual cost-effectiveness model established the incremental cost per 52-week quitter, while a Markov model was developed for the lifetime analysis to estimate the potential lifetime outcomes in terms of cost per quality-adjusted life years (QALY) gained, to account for the benefits quitters will receive in terms of extended life years and improvements in quality of life from smoking cessation. The proportion of carbon monoxide-validated quitters from both services combined fell from 22.5% at 4-week follow-up to 3.6% at 52 weeks. The group service achieved a higher quit rate (6.3%) than the pharmacy service (2.8%) but was more intensive and required greater overhead costs. The lifetime analysis resulted in an incremental cost per QALY of 4,800 pound for the group support and 2,600 pound for pharmacy one-to-one counseling. Despite disappointing 1-year quit rates, both services were considered to be highly cost-effective.

UR - http://www.scopus.com/inward/record.url?scp=79251581611&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1093/ntr/ntq222

U2 - 10.1093/ntr/ntq222

DO - 10.1093/ntr/ntq222

M3 - Article

VL - 13

SP - 135

EP - 145

JO - Nicotine & Tobacco Research

JF - Nicotine & Tobacco Research

SN - 1462-2203

IS - 2

ER -